Friday, February 3, 2017 Catherine Stehman-Breen Home Address: REDACTED Dear Catherine: (May 4th, 2017)
On behalf of Sarepta Therapeutics, Inc. ("Sarepta" or the "Company"), it is a great pleasure to extend you this offer of employment as Chief Medical Officer in Cambridge, MA effective on a date agreed upon following your acceptance of this offer ( "Hire Date"), reporting to Edward M. Kaye, Chief Executive Officer.
Asset Purchase Agreement by and Between Gilead Sciences, Inc. And Sarepta Therapeutics Inc. (May 4th, 2017)
This Asset Purchase Agreement (this "Agreement") is made and entered into as of February 20, 2017 (the "Effective Date"), by and between GILEAD SCIENCES, INC., a corporation organized under the laws of the Delaware ("Buyer"), and SAREPTA THERAPEUTICS INC., a corporation organized under the laws of Delaware ("Seller"). Buyer and Seller may hereinafter be referred to individually as a "Party" and collectively as the "Parties".
Sarepta Therapeutics, Inc. EMPLOYMENT AGREEMENT (November 7th, 2016)
EMPLOYMENT AGREEMENT (this "Agreement") dated as of September 20, 2016, between Sarepta Therapeutics, Inc., a Delaware corporation (the "Company"), and Edward M. Kaye, M.D. (the "Executive").
LICENSE AND COLLABORATION AGREEMENT by and Between SUMMIT (OXFORD) LTD and SAREPTA THERAPEUTICS, INC. Dated as of October 3, 2016 (November 7th, 2016)
Contract (October 4th, 2016)
Sarepta Therapeutics and Summit Enter Into Exclusive License and Collaboration Agreement for European Rights to Summits Utrophin Modulator Pipeline for the Treatment of Duchenne Muscular Dystrophy
5,020,921 Shares Sarepta Therapeutics, Inc. Common Stock ($0.0001 Par Value) EQUITY UNDERWRITING AGREEMENT (September 23rd, 2016)
First Amendment to License Agreement (August 9th, 2016)
This first amendment to the License Agreement ("First Amendment") is made and entered into as of this 19th day of June, 2016 ("First Amendment Effective Date") by and between The University of Western Australia, a body corporate established pursuant to the provisions of The University of Western Australia Act 1911, with offices at 35 Stirling Highway, Crawley, Western Australia 6009 ("UWA"), on the one hand, and Sarepta Therapeutics, Inc., with offices at 215 First Street, Cambridge, MA 02142, USA ("Sarepta") and Sarepta International CV ("Sarepta Netherlands," and collectively with Sarepta, "Licensee"), on the other hand.
2,102,000 Shares Sarepta Therapeutics, Inc. Common Stock ($0.0001 Par Value) EQUITY UNDERWRITING AGREEMENT (June 10th, 2016)
Separation and Consulting Agreement and General Release (August 6th, 2015)
This Separation and Consulting Agreement and General Release (the Agreement) by and between Chris Garabedian (Executive) and Sarepta Therapeutics, Inc. (the Company), is made effective as of the eighth (8th) day following Executives signature without revocation (the Effective Date) with reference to the following facts:
Sarepta Therapeutics, Inc. Executive Employment Agreement (May 7th, 2015)
This Employment Agreement (the Agreement) is entered into as of April 1, 2015 (the Effective Date) by and between Sarepta Therapeutics, Inc. (the Company), and Edward M. Kaye, M.D. (Executive).
Avi Biopharma, Inc. Executive Employment Agreement (August 8th, 2011)
This Employment Agreement (the Agreement) is entered into as of June 13, 2011 (the Effective Date) by and between AVI BioPharma, Inc. (the Company), and Edward M. Kaye, M.D. (Executive).
Avi Biopharma, Inc. Stand Alone Stock Option Grant Notice of Grant of Stock Option (June 20th, 2011)
This grant (the Option) shall be governed by this Notice of Grant of Stock Option (the Notice of Grant) and the Terms and Conditions of Stock Option Grant (the Terms and Conditions), attached hereto as Exhibit A (together, the Agreement). Terms not otherwise defined in the Notice of Grant shall be defined in the Terms and Conditions of Stock Option Grant.